Welcome to our dedicated page for Amneal Pharmaceuticals SEC filings (Ticker: AMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations, capital structure, and governance. This page brings together those SEC filings and pairs them with AI-powered tools to help readers interpret the information more efficiently.
For Amneal, current reports on Form 8-K are a key source of timely disclosures. Recent 8-K filings describe quarterly financial results, including net revenue trends across the Affordable Medicines, Specialty, and AvKARE segments, as well as updates to full-year guidance. Other 8-Ks outline significant financing transactions, such as new seven-year term B loans, senior secured notes due 2032, and amendments to the company’s revolving credit agreement, along with details on collateral, covenants, and maturity profiles.
Filings also cover governance and stockholder matters. For example, Amneal has reported preliminary financial results, changes to board composition when designation rights shifted under a stockholders agreement, and the board’s decision to hold Say-on-Pay advisory votes on an annual basis following stockholder preferences expressed at an annual meeting.
On this page, users can access Amneal’s Forms 8-K and, through links to its broader filing history, locate annual reports on Form 10-K and quarterly reports on Form 10-Q. These longer-form filings typically include segment discussions for Affordable Medicines, Specialty, and AvKARE, risk factor summaries, and explanations of non-GAAP measures such as adjusted EBITDA and adjusted diluted EPS referenced in earnings releases.
AI features on the platform provide summaries and highlights of lengthy filings, helping readers identify key topics such as segment performance, debt structure, covenant changes, and governance decisions without reading every line. Users interested in AMRX can use this page to monitor new filings as they appear on EDGAR, review historical disclosures, and better understand how regulatory documents reflect Amneal’s evolving business and capital structure.
Insider sales by Amneal Pharmaceuticals officer. Nikita Shah, identified as Executive Vice President and reporting person, sold a total of 120,832 shares of Amneal Pharmaceuticals, Inc. (AMRX) in two transactions: 114,492 shares on 08/22/2025 at a weighted-average price of $9.66 and 6,340 shares on 08/25/2025 at a weighted-average price of $9.50. Following these disposals the filing shows beneficial ownership of 146,403 shares. The Form 4 was signed by an attorney-in-fact on 08/25/2025. The filing provides weighted-price ranges for the sales and offers to provide detailed per-transaction quantities on request.
Andrew S. Boyer, Executive Vice President of Amneal Pharmaceuticals (AMRX), reported insider transactions executed on 08/20/2025. He exercised 175,000 stock options at a $2.75 exercise price, acquiring 175,000 Class A common shares. On the same date he sold 279,244 Class A common shares at a weighted average price of $9.38, with sale prices ranging from $9.30 to $9.40 per share.
After these transactions the Form 4 shows Mr. Boyer beneficially owned 431,670 Class A shares before the sale line and 152,426 Class A shares following the sale line, and held 97,480 options (derivative securities) after the reported option exercise. The filing was signed by an attorney-in-fact on 08/22/2025 and notes the exercised options were fully vested.
Amneal Pharmaceuticals (AMRX) Form 144 notice records a proposed sale of 36,796 Class A shares with an aggregate market value of $356,921, intended for sale on 08/22/2025 on NASDAQ. The filer reports the shares were acquired as equity compensation from Amneal Pharmaceuticals on 03/01/2023 (18,628 shares) and 03/03/2023 (18,168 shares). The filing also discloses three recent sales by the same person during August 2025 totaling 205,730 Class A shares for gross proceeds of $1,935, - [aggregate per rows: $818,930; $663,065; $453,000]. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information and carries the required signature and warning about false statements.
Amneal Pharmaceuticals, Inc. (AMRX) Form 144 indicates a proposed sale of 84,036 common shares through Charles Schwab, with an aggregate market value of $818,930.82. The filing lists approximately 314,079,309 shares outstanding and an approximate sale date of 08/22/2025 on NASDAQ. The securities were acquired on 07/05/2018 as executive compensation. The filing also discloses two recent sales by the named person: 71,694 shares sold on 08/14/2025 for $666,037.26 and 50,000 shares sold on 08/12/2025 for $452,030.89. The signer represents they are not aware of any undisclosed material adverse information about the issuer.
Amneal Pharmaceuticals (AMRX) reported a Form 144 notice showing proposed sales by an affiliate. The filer intends to sell 175,000 Class A shares with an aggregate market value of $1,637,900, against approximately 314.08 million shares outstanding, with an approximate sale date of 08/20/2025 on NASDAQ. The filing records the shares were acquired as stock options on 05/07/2018 from Amneal Pharmaceuticals. The form also discloses prior sales in the past three months totaling 137,680 Class A shares for gross proceeds of $1,272,163 (sales on 08/12/2025 and 08/20/2025). The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Form 144 notice for Amneal Pharmaceuticals, Inc. (AMRX) reports a proposed sale of 104,244 common shares with an aggregate market value of $969,469, to be effected approximately on 08/20/2025 on NASDAQ through Charles Schwab.
The filing shows those 104,244 shares were acquired as restricted stock awards on multiple dates between 02/27/2022 and 03/03/2024 and paid as equity compensation. The issuer's total outstanding shares are reported as 314,079,309. The filing also discloses a prior sale by an identified seller, Andrew Boyer, of 33,436 shares on 08/12/2025 for $302,694. The signer certifies no undisclosed material adverse information and includes the standard Rule 144 representations.
Nikita Shah, Executive Vice President of Amneal Pharmaceuticals, Inc. (AMRX), reported the sale of 71,694 shares of Class A common stock on 08/14/2025 at a weighted-average price of $9.29 per share, with individual trade prices ranging from $9.16 to $9.41. After the reported dispositions, the reporting person beneficially owned 267,235 shares, held directly. The Form 4 was filed indicating the transaction type as a sale and includes an explanatory footnote that the reported price is a weighted average from multiple trades. The form is signed by an attorney-in-fact on 08/15/2025.
Amneal Pharmaceuticals (AMRX) insider selling reported on Form 4. Executive Vice President & CFO Tasos Konidaris disposed of a total of 499,730 shares across three sale dates: 161,365 shares on 08/13/2025 at a weighted average price of $9.22, 119,206 shares on 08/14/2025 at $9.30, and 219,159 shares on 08/15/2025 at $9.43. After these transactions the reporting person beneficially owned 122,152 shares.
The filing shows the sales were executed in multiple transactions with price ranges disclosed in footnotes and signed by an attorney-in-fact. No derivative transactions, grants, or acquisitions are reported on this form and no explanatory statements beyond weighted-average price ranges were provided.
Insider sale notice for Amneal Pharmaceuticals (AMRX). The Form 144 reports a proposed sale of 219,159 common shares with an aggregate market value of $2,057,903.01 to be sold on or about 08/15/2025 on NASDAQ. The filing shows the securities were acquired through RSU vesting on three dates in March 2024 totaling 219,159 shares. The document also discloses recent completed sales by Anastasios Konidaris: 161,635 shares sold on 08/13/2025 for gross proceeds of $1,489,993.93 and 119,206 shares sold on 08/14/2025 for gross proceeds of $1,108,993.36. The filer certifies they are not aware of undisclosed material adverse information about the issuer.
Amneal Pharmaceuticals (AMRX) Form 144: This notice reports a proposed sale of 71,694 Class A shares (aggregate market value $663,065) to be sold on or about 08/14/2025 on NASDAQ. The shares were acquired through equity compensation from Amneal Pharmaceuticals on 02/27/2024 (16,950 shares), 03/01/2024 (13,776 shares) and 03/03/2024 (40,968 shares), matching the 71,694 units listed. The filing lists the total Class A shares outstanding as 314,079,309. The notice also discloses sales by the same person in the past three months: 50,000 shares sold on 08/12/2025 for $453,000 and 49,140 shares sold on 05/16/2025 for $370,542. By signing, the seller represents they possess no undisclosed material information about the issuer.